The seventh batch of national pricking drugs for the average price reduction of 48%, the minimum quotation of "Fluid God of Medicine" Oasiswu is 0.99 yuan/piece

China Times (chinatimes.net.cn) reporter Guo Yilin Yu Na Beijing reporting

The seventh batch of national collection has gradually opened the bidding. This procurement has been included in 61 kinds of medicines. The average price reduction of the selected drugs is 48%. According to the agreed purchase volume, it is expected to save 18.5 billion yuan per year.

At 10 am on July 12, under the organization and guidance of relevant departments such as the State Medical Insurance Bureau, provinces across the country formed a procurement alliance to carry out the seventh batch of centralized national drug procurement in Nanjing, Jiangsu. According to this process, the confirmation time of the supply area of ​​this collection is divided into two batches. In this way, the first batch was announced at 4 pm on July 12; the second batch was opened at 9 am on July 13.

Compared with the first six episodes, the seventh batch of collection of "substitute mechanisms" was introduced for the first time to strengthen the supply guarantee. This means that when the original Chinese selected enterprise cannot be supplied, the alternative enterprise will be supplied at the winning price of the selected enterprise.

The proposed company Hanyu Pharmaceutical was interviewed by a reporter from the Huaxia Times, "The company has set up a special production base, which can not only meet the existing orders, but also provide guarantees for the supply after collection. In addition, the base of Wuhan will also be. In the future, supplement the production capacity of raw medicines, and multi -pronged trials and capacity. "

The average price reduction of drugs is 48% of the selected drugs

On the morning of July 12, the seventh batch of national sets were generated in Nanjing, Jiangsu. The results of the official selection will be released after the publicity. The collection of 60 drugs in this collection is successful. The average price reduction of drugs is planned to be selected by 48%. According to the agreed purchase volume, it is expected to save 18.5 billion yuan per year.

According to the rules, the company's declaration variety must obtain effective domestic registration approval before July 7, 2022, and the information declaration should be completed before 00:00 on July 10, 2022. Like the collection of several times in the past, there are also companies stepped into the game in this collection, successfully set foot in the last train of this round of national pricking.

The large market size and sufficient competition have always been the focus of collection, and the seventh batch of national optics also continues the trend of large varieties. Judging from the sales of the seventh batch of varieties in the Chinese public medical institution in 2021, the total market size of the variety exceeded 30 billion yuan, led by 2 over 6 billion major varieties of Nizetz -horizon -controlled release type and Moro Peinan injection. Omeprazole injection competition is the most intense, and 28 pharmaceutical companies have met the competition conditions.

It is reported that the collection of the collection was hot, and the participation of pharmaceutical companies was enthusiastic. The 488 products of 295 companies participated in the bidding, and the 327 products of 217 companies were qualified for the selection. Among them, 6 of the six international pharmaceutical companies were selected, and 211 domestic pharmaceutical companies were selected as 321 products. The proportion of bidding companies was 73%. The average variety of drugs is selected by 5.4 companies, and the supply of diversification and stability has been further enhanced.

This procurement is included in 61 drugs, involving 31 treatment categories, including common diseases such as hypertension, diabetes, anti -infection, digestive tract diseases, and major diseases such as lung cancer, liver cancer, kidney cancer, bowel cancer and other diseases. The benefit is wide and strong.

Taking the first -line liver cancer -targeted Yaolunbutoni capsule as an example, the price of each capacity drops from an average of 108 yuan to an average of 18 yuan, and a treatment cycle can save 8,100 yuan. For the first time in the field of lowering blood pressure, it was included in the slow -controlled release agent. The price of nifeding horizontal control was 58%reduced, and the price of Matolol's slow -release tablet was 53%. The burden on the medication of patients with hypertension was significantly reduced. Anti -virus drug Oasis Veve's price reduced from average of 4.5 yuan to 1 yuan. In addition, Pfizer's Donalin, Japan's Anstelai Mikafen Pure, Emmiro of Spain, Emmoro, and Bryko Xinyi, Italy, 4 original research medicines In the election, the average price was reduced by 67%.

The minimum quotation of Osdowei is 0.99 yuan/piece

It is worth noting that in today's seventh batch of national drugs procurement, the "influenza magical medicine" Olyva Veye's price reduction due to the influenza in the southern summer has attracted attention. The minimum quotation is 0.99 yuan/piece, and the bidding enterprise is East Sunshine, and the price of this variety is 6.45 yuan/piece.

Osdowe is a classic drug in anti -influenza drugs, known as the "king of influenza drugs". As a specific inhibitor of neuropine enzymes, Oasiswei is out of the host cells by inhibiting mature influenza viruses from the host cells, thereby inhibiting the spread of influenza viruses in the human body, in order to treat influenza. Influenza treatment.

In this collection, Oasis Weigou has three specifications in the procurement list, which are 30 mg, 45mg, and 75mg, respectively. Company, Dongyang Guang, Jiangsu Nuotai Ao Sano Biopharmaceutical Co., Ltd., Chengdu Beite Pharmaceutical Co., Ltd., Natco Pharma Limited, Qilu Pharmaceutical (Hainan) Co., Ltd. Pharmaceutical Research and Development Co., Ltd., Stone Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd., Borui Pharmaceutical (Suzhou) Co., Ltd., Zhejiang Huahai Co., Ltd., Zhongshan Wanhan Pharmaceutical Co., Ltd., Xidelong Pharmaceutical (Beijing) Co., Ltd. Yipin Red Pharmaceutical Co., Ltd.. It is worth mentioning that some of them are Olympic drug registration certificates that have just obtained this year.

In fact, with this collection, Oswawei's market competition pattern will also face changes. Over the years, East Sunshine has been a unique market in the Austrian market competition, accounting for nearly 90 % of the market share. In 2019, the total sales revenue of the particle dosage and capsule dosage of the drug was close to 6 billion yuan. According to Mine.com, in 2019, in Chinese public medical institutions and Chinese urban physical pharmacies, Osdim Weirou's total sales exceeded 6.5 billion yuan. In the past 2020 and 2021, due to the low influenza, Olyva's sales have fallen sharply. According to the data of Zhongkang Technology, in 2021, the unit price of the terminal sales of the drug in the retail market and level hospitals was 73.99 yuan and 58.74 yuan, respectively, a decrease of 6.6 yuan and 19.3 yuan from 2020.

Even so, East Sunshine Oshewei still occupies the market leading position. Since June 2022, the H3N2 influenza has raided in many provinces and cities in the south, which has spawned the market for the strong demand for Olympic Weil. In this context, recently, the selling price of the "Kewei" capsule terminal of the East Sunshine once exceeded hundreds of yuan per box. Now, with the upcoming bidding, East Sunshine Ostewell's unique pattern in the market competition is broken.

Regarding the changes brought by the collection to the industry, Shi Lichen, a medical strategic marketing expert, accepted an interview with the reporter of the Huaxia Times, "After several years of exploration, the results of the country's volume procurement have been initially appeared. With the advancement of collection, pharmaceutical companies The layout of the product level will also be accelerated, and the research and development structure will also change. Pharmaceutical companies will gain profits with innovative drugs, and the gray profit space will be further squeezed. Regional marketing capabilities have been weakened further. "

The reporter learned from the State Medical Insurance Bureau that since the establishment of the State Medical Insurance Administration in 2018, it has carried out seven batches of centralized procurement of drugs in national organizations, covering a total of 294 kinds of medicines, and calculated by the pre -mining price. 35%of the annual procurement amount, concentrated band procurement has become an important model for drug procurement of public hospitals. In the next step, the National Medical Insurance Administration will work with relevant departments to guide the implementation of the selection results in various places and middle school companies to ensure that patients across the country use the selected products after the collection of prices in November 2022.

Xuexue Editor: Editor of Yan Yuan: Chen Yanpeng

- END -